Floatz logo

Icovamenib

Progression

Biomea Fusion Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Progression cohort.

Asset / SponsorPhaseRating
Carboplatin
Sun Yat-sen University
Phase 3B
Irinotecan
Kyorin University
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 3B
(+)-VINCRISTINE
Kyorin University
Phase 3B
ETOPOSIDE
Sun Yat-sen University
Phase 3B
Everolimus
AC Camargo Cancer Center
Phase 2CCC

Same molecule, other indications

Icovamenib is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
mixed phenotype acute leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →